ijms-logo

Journal Browser

Journal Browser

Neurodegenerative Disorders: Advances in Mechanisms, Models, and Therapeutics

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: 20 July 2026 | Viewed by 1032

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA, USA
Interests: neurodegenerative disorders; TDP-43; C9orf72; dipeptide repeat; proteotoxicity; cryptic exon exclusion; L-BMAA

Special Issue Information

Dear Colleagues,

We are pleased to announce a Special Issue of the International Journal of Molecular Sciences (IJMS) titled “Neurodegenerative Disorders: Advances in Mechanisms, Models, and Therapeutics.” This Special Issue will highlight cutting-edge research on the molecular and cellular mechanisms underlying neurodegenerative diseases, with a focus on aging, disease pathogenesis, therapeutic interventions, and preclinical models.

Neurodegenerative disorders—including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis—present significant challenges due to their complex pathology and limited treatment options. We welcome original research articles, as well as full- and mini-reviews addressing key aspects such as genetic and epigenetic contributions, protein aggregation, neuroinflammation, and synaptic alterations driving disease progression. Additionally, studies on innovative therapeutic strategies, drug discovery, and advanced disease models are highly encouraged.

We also invite insightful reviews exploring the limited success of recent treatment approaches and the challenges in translating research findings into clinical practice. We hope that this Special Issue will be of great interest to researchers in molecular neuroscience, pharmacology, and translational medicine.

We look forward to your contributions in advancing the field.

Dr. Craig Bennett
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • TDP-43
  • C9orf72
  • dipeptide repeat
  • proteotoxicity
  • cryptic exon exclusion
  • L-BMAA

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

24 pages, 4666 KB  
Article
PPAR-Delta Agonist Therapies Did Not Rescue Hallmark Disease Phenotypes in Two Sets of Preclinical Trials in ALS TDP-43 and C9orf72 Model Mice
by David T. Luong, Chenchen Niu, Eunice Kim, Nolan Tanji, Ivy Duong, Brandon Galero, Yong-Jie Zhang, Craig L. Bennett and Albert R. La Spada
Int. J. Mol. Sci. 2026, 27(4), 1820; https://doi.org/10.3390/ijms27041820 - 13 Feb 2026
Viewed by 539
Abstract
Peroxisome-proliferator–activated receptor delta (PPARδ) regulates metabolic, mitochondrial, and inflammatory pathways implicated in neurodegeneration, making it an attractive therapeutic target for amyotrophic lateral sclerosis (ALS). In this study, we evaluated two PPARδ agonists, KD3010 and T3D-959, in two established ALS/FTD mouse models: an AAV-mediated [...] Read more.
Peroxisome-proliferator–activated receptor delta (PPARδ) regulates metabolic, mitochondrial, and inflammatory pathways implicated in neurodegeneration, making it an attractive therapeutic target for amyotrophic lateral sclerosis (ALS). In this study, we evaluated two PPARδ agonists, KD3010 and T3D-959, in two established ALS/FTD mouse models: an AAV-mediated C9orf72 G4C2-repeat expansion model (C9-149R) and the TDP-43Q331K transgenic model. Drug treatment was initiated prior to the emergence of key disease features and continued for 9–10 months. Comprehensive behavioral, neuropathological, and biomarker analyses revealed marked differences between the two models. C9-149R mice exhibited reduced body weight and subtle behavioral alterations without robust motor deficits, whereas TDP-43Q331K mice developed pronounced, progressive motor and cognitive impairments accompanied by a ~7-fold elevation in plasma neurofilament light chain (NfL). Despite effective target engagement—particularly for T3D-959—neither PPARδ agonist improved motor performance, cognitive behavior, neuroanatomical measures, plasma NfL levels, or disease-associated molecular phenotypes in either model. Prolonged KD3010 treatment resulted in loss of target engagement, consistent with drug tolerance, while T3D-959 sustained PPARδ activation without therapeutic benefit. Together, these findings demonstrate that PPARδ agonism is insufficient to modify disease progression in these ALS/FTD mouse models and underscore the importance of publishing well-powered negative preclinical studies to refine therapeutic strategies for ALS. Full article
Show Figures

Figure 1

Back to TopTop